Human papillomavirus-related head and neck tumors: clinical and research implication

  title={Human papillomavirus-related head and neck tumors: clinical and research implication},
  author={Amanda Psyrri and Panagiotis Gouveris and Jan Baptist Vermorken},
  journal={Current Opinion in Oncology},
Purpose of review High-risk human papillomaviruses (HPVs) are implicated in the development of a subset of head and neck squamous cell cancers (HNSCCs), especially those arising from the lingual or palatine tonsils. HPV-associated HNSCCs represent a different disease entity from those associated with the traditional risk factors of tobacco and alcohol use. The demonstration that HPV is causally associated with a subset of HNSCC has tremendous clinical and research implications. Recent findings… 

Human papillomavirus in head and neck cancers: biology, prognosis, hope of treatment, and vaccines

This study summarizes the current knowledge regarding the epidemiology, biology, malignant transformation mechanisms, and prognosis of HPV-associated HNSCCs, and underlines the clinical implications of related treatments and prophylactic strategies.

The Role of Human Papillomavirus in Head and Neck Cancers

Investigations suggest that HPV infection in these anatomic sites is an independent risk factor for carcinogenesis, and the most frequently detected high-risk HPVs in HNSCC are the 16 and 18 genotypes.

Human Papilloma Virus in Head and Neck Squamous Cell Cancer

HPV infection has a significant impact on Head and Neck Squamous Cell Carcinomas, and despite HPV-16 stronger impact, HPV-18 is more likely to cause malignant degeneration in such cancers amongst some communities.

Human Papillomavirus: Changing Paradigms in Oropharyngeal Cancer

Patients with an HPV-associated oropharyngeal cancer have a distinctly better survival after treatment than those patients with HPV-negative tumors, although their prognosis is significantly worse if there is a history of tobacco abuse.

HPV status and overall survival of patients with oropharyngeal squamous cell carcinoma--a retrospective study of a German head and neck cancer center.

A prevalence of HPV-positive tumors within OSCC is confirmed, confirming its epidemiologic and prognostic relevance, and HPV status should be considered an important part of tumor staging.

Next‐generation treatment strategies for human papillomavirus‐related head and neck squamous cell carcinoma: where do we go?

Present therapeutic HPV‐targeting strategies are focused on, future directions for de‐intensified treatment of HPV‐positive HNSCC are discussed and the development and future use of new antiviral and immunomodulatory therapeutics are discussed.

Rethinking the head and neck cancer population: the human papillomavirus association.

  • C. Callaway
  • Medicine
    Clinical journal of oncology nursing
  • 2011
High-risk strains of the human papillomavirus (HPV) already are associated with cervical, oral, and anal cancers; however, HPV DNA has been detected in about a third of head and neck malignancies.



Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

It is suggested that HPV-positive oropharyngeal cancers comprise a distinct molecular, clinical, and pathologic disease entity that is likely causally associated with HPV infection and that has a markedly improved prognosis.

Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil

Patients with HPV‐positive tumours were significantly less likely to have recurrence or to die of disease than those with HPV-negative tumours, after adjusting for the effects of the cell cycle proteins, clinical stage, pathological node status, tumour grade, age, gender and treatment.

Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.

HPV-16 infection may be a risk factor for squamous-cell carcinoma of the head and neck in subjects who were seropositive for HPV-16, and no increased risk was observed for other HPV types.

Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.

For patients with metastatic HNSCC, detection of HPV-16 is a reliable way to establish origin from the oropharynx, either directly by ISH or indirectly by immunohistochemistry for p16 overexpression.

Human papillomavirus (HPV) in head and neck cancer.

  • S. Syrjänen
  • Medicine
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • 2005

Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx

HP status was identified as an independent prognostic factor in oral and oropharyngeal cancers and appeared to be gender‐specific, suggesting the need for further study of the interaction between HPV and gender on survival.

High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.

  • L. LicitraF. Perrone S. Pilotti
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
The molecular and clinical results are in agreement with previous findings but provide additional information into the biologic mechanisms involved in HR-HPV oropharyngeal cancer in comparison to HPV-negative tumors.

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

For patients with HNSCC of the oropharynx, tumor HPV status is strongly associated with therapeutic response and survival and, after adjustment for age, tumor stage, and ECOG performance status, lower risks of progression and death are found.

Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.

  • P. WeinbergerZiwei Yu A. Psyrri
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
A novel classification scheme that may have value for patient stratification for clinical trials testing HPV-targeted therapies is defined, namely HPV+/p16 high (class III) in oropharyngeal squamous cell carcinoma.

Human papillomavirus in HNSCC: a European epidemiologic perspective.